Etiometry Raises $9M in Series A-3 Funding

Etiometry, a Boston, MA-based provider of clinical decision-support software for the intensive care environment, raised $9M in Series A-3 funding.

The round was led by SKK 9i Ventures, with participation from Shamrock Holdings and other healthcare investors.

The funds will be used to help extend use of the company’s software to other hospital care settings.

Led by Shane Cooke, CEO, Etiometry provides clinical decision-support software for the intensive care environment. The software aggregates patients’ vital signs from multiple sources into one streamlined platform to help clinicians understand evolving clinical risks and make data-driven patient care decisions. Its technologies are currently in use in more than 20 of the top children’s hospitals in the United States.

The company obtained its sixth 510(k) clearance from the FDA in 2020 and anticipates its seventh clearance to be granted in the second half of 2021 for new risk algorithms.

To support the commercial expansion, Etiometry expanded its leadership team with three new hires:

  • Jeff Gaus, VP of Sales,
  • Howard Brick, Chief Strategy Officer, and
  • Brad Rosenblum, Chief Financial Officer.